Repeated otilonium bromide administration prevents neurotransmitter changes in colon of rats underwent to wrap restraint stress. by Traini, Chiara et al.
Repeated otilonium bromide administration prevents
neurotransmitter changes in colon of rats underwent to wrap
restraint stress
Chiara Traini a, Stefano Evangelista b, Vincent Girod c, Maria Simonetta Faussone-Pellegrini a,
Maria Giuliana Vannucchi a, *
a Department of Experimental and Clinical Medicine, Research Unit of Histology and Embryology, Florence, Italy
b Ricerche SpA, Preclinical Development Dept., Florence, Italy
c Syncrosome, Marseille, France
Received: June 28, 2016; Accepted: September 14, 2016
Abstract
Otilonium bromide (OB) is a spasmolytic drug successfully used for the treatment of irritable bowel syndrome (IBS). Its efficacy has been attrib-
uted to the block of L- and T-type Ca2+ channels and muscarinic and tachykinin receptors in the smooth muscle. Furthermore, in healthy rats,
repeated OB administration modified neurotransmitter expression and function suggesting other mechanisms of action. On this basis, we inves-
tigated whether repeated OB treatment prevented the functional and neurochemical changes observed in the colon of rats underwent to wrap
restrain stress (WRS) a psychosocial stressor considered suitable to reproduce the main IBS signs and symptoms. In control, WRS and OB/
WRS rats functional parameters were measured in vivo and morphological investigations were done ex vivo in the colon. The results showed
that OB counteracts most of the neurotransmitters changes caused by WRS. In particular, the drug prevents the decrease in SP-, NK1r-, nNOS-,
VIP-, and S100b-immunoreactivity (IR) and the increase in CGRP-, and CRF1r-IR. On the contrary, OB does not affect the increase in CRF2r-IR
neurons observed in WRS rats and does not interfere with the mild mucosal inflammation due to WRS. Finally, OB per se increases the Mr2
expression in the muscle wall and decreases the number of the myenteric ChAT-IR neurons. Functional findings show a significantly reduction
in the number of spontaneous abdominal contraction in OB treated rats. The ability of OB to block L-type Ca2+ channels, also expressed by
enteric neurons, might represent a possible mechanism through which OB exerts its actions.
Keywords: corticotrophin releasing factor receptors immunohistochemistry nerve structures inflammation irritable bowel
syndrome otilonium bromide smooth muscle cells rat colon
Introduction
Otilonium bromide (OB) – also known by its IUPAC chemical name N,
N-diethyl-N-methyl-2-(4-[2-(octyloxy)benzamido]benzoyloxy)ethana-
minium bromide – is prescribed in Europe, Asia and South America
as an anti-spasmodic for the treatment of irritable bowel syndrome
(IBS) [1]. This drug contains a charged quaternary ammonium that
favours its accumulation within the gastrointestinal wall [2]. The OB
spasmolytic activity is mainly because of the interference of calcium
influx through L-type Ca2+ channels and the mobilization of cellular
calcium required for smooth muscle contraction, thereby limiting
excessive intestinal contractility. Otilonium bromide also inhibits T-
type Ca2+ channels and muscarinic and tachykinin receptors (NK1r
and NK2r) on smooth muscle and primary afferent neurons that may
have the joint effect of reducing motility and abdominal pain [3].
Indeed, in strips of human colon, exposure to OB, either alone or in
the presence of the tachykinin agonist, caused a concentration-
dependent reduction in the number of the cells that internalized the
receptor NK2r [4].
A recent clinical trial has confirmed the OB efficacy in IBS patients
and has shown, for the first time, the long-term beneficial effect of
the drug during the follow-up period in a group of patients previously
treated with OB as compared to placebo group [5]. These findings
suggest that OB given in a long-term way is able to preserve the clini-
cal beneficial effects beyond its interruption.
Several experiments have been done in rats repeatedly treated
with OB to ascertain its cellular targets and mechanisms of
action. The results obtained demonstrated: in the smooth muscle
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cells, morphological changes in the structures involved in cal-
cium handling and storage (caveolae, smooth endoplasmic reticu-
lum, mitochondria) and in the NK1r distribution and Mr2
expression; in the enteric neurons, immunohistochemical and
functional changes in the nNOS/SP/NK1r mediated signalling
circuit [6–8].
Colonic biopsies from IBS patients show an increase in activated
lymphocytes, mast cells, and neutrophilic and eosinophilic granulo-
cytes in the mucosa suggestive for a local inflammation [9, 10].
Moreover, an increase in the transient receptor potential vanilloid 1
no-selective ionic channel and SP expression has been reported and
related to pain [11]. A main role in the aetiopathogenesis of IBS has
been attributed to a psychosocial stress and animal models based on
this hypothesis and reproducing some of the most common IBS
symptoms have been developed. We recently demonstrated in rats
underwent to the wrap restrain stress (WRS) the development of an
increased colonic activity and faecal excretion and, as in IBS patients,
a mild inflammation in the mucosa [12]. Interestingly, we also found
important changes in glial cells and in excitatory and inhibitory neuro-
transmitters in the entire colonic wall, and an increase in CRF1r
expressing myenteric neurons.
The peculiar features of the WRS model make it particularly suit-
able to investigate the ability of OB to prevent or attenuate the appear-
ance and evolution of the colonic alterations induced by stress.
Therefore, this study was aimed to investigate whether a repeated
treatment with OB prevented the functional and immunohistochemical
changes characterizing the WRS rats.
Materials and methods
Animals
Male Wistar rats (n = 71) from Janvier Labs (Saint-Berthevin, France)
weighing around 250–350 g on the day of experiments were used for
this study and housed at Syncrosome Laboratories (Marseille, France).
The acclimatization of the animals lasted at least 5 days. They had free
access to food and drinking water ad libitum. The experimental proce-
dures were carried out in accordance to European guidelines for the
care and use of laboratory animals (Directive 2010/63/UE) and were
approved by the French Ethical Committee C2EA-/71, of which Syncro-
some is a member. Every effort was done to maintain animal’s health,
safety and welfare, minimize suffering and reduce the number of ani-
mals used in the experiments. Furthermore, Syncrosome laboratories
and its animal housing facilities are accredited by French Authorities
and audited every year by French Department of Veterinary Service.
Study plan
The study was divided into two consecutive phases. The first phase
was carried out to better define the OB dose to be used in the second
one, consisting in the main session of experiments. First phase: OB
was given 4 hrs before colorectal distension (CRD) and abdominal con-
traction (AC) recordings at doses of 2 or 20 mg/kg p.o. (Fig. 1 and
Table S1). These doses and time were chosen on the basis of previous
Fig. 1 Study plan. First phase: OB was given at 2 mg/kg and at 20 mg/kg, 5 ml/kg, 4 hrs before colorectal distension (CRD). WRS was induced for
2 hrs. Second phase: OB given at 20 mg/kg, 5 ml/kg, was administered for 10 days before inducing WRS.
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experiments [6, 7] and of pharmacokinetic properties of the drug [2].
Second phase: The chosen OB dose of 20 mg/kg was administered for
10 days and on the day 11, the rats received the last dose 4 hrs before
undergoing to CRD (Fig. 1 and Table S1). In both phases, rats were sub-
jected to WRS for 2 hrs, starting at 1.5 hrs after the last OB administra-
tion. For the total number of rats used for each phase, see Table S1.
OB preparation and administration
The drug was dissolved in water at final concentrations of 0.4 and
4 mg/ml and a total volume of 5 ml/kg was administered to reach the 2
or 20 mg/kg dose respectively. The controls received an equal volume
of water. Otilonium bromide was given p.o. For the first phase, OB was
administered once at Day 0 (D0) 4 hrs before CRD test; for the second
phase OB was administered twice daily from D10 to D0 and the last
dose on D0 4 hrs before CRD test (Fig. 1 and Table S1).
Application of WRS and functional evaluations
The application of WRS consists in the block of the upper forelimbs
and thoracic trunk for 2 hrs. The timing and the procedure of WRS
application was described in detail in Data S1. Faecal pellet collection
and ACs following colorectal distention by the insertion of a balloon
were chosen as functional parameters. The details about the timing of
functional evaluations and methods were explained in Data S1.
Tissue sampling
As depicted on Figure 1 and Table S1, the animals that did not undergo to
CRD were killed at T0 with pentobarbital and the colon was removed. In
particular, three full-thickness samples (length: 1 cm/each) of the ascend-
ing colon (starting 1 cm far from the ileo-caecal junction) were taken from
each experimental group and randomly assigned to the different proce-
dures described below. For paraffin embedded tissue, the sample was
fixed in 4% paraformaldehyde in 0.1 M phosphate buffered saline (PBS,
pH 7.4) over night (ON) at 4°C, dehydrated in graded ethanol series,
cleared in xylene and embedded in paraffin. Then, the sections (5 lm
thick) were cut using a rotary microtome (MR2; Boeckeler Instruments
Inc., Tucson, AZ, USA) and collected on positively charged slides. For fro-
zen tissue, a second sample after fixation was cryoprotected with 30%
sucrose in PBS ON at 4°C, embedded in Killik cryostat medium (Bio-
Optica, Milan, Italy) and frozen at 80°C. Transverse cryosections (8 lm
thick) were cut using a cryostat (Leica Microsystem CM 1950, Wetzlar,
Germany) and collected on positively charged slides. For western blot
analysis, a third sample was quickly frozen in liquid nitrogen and stored at
80°C. To evaluate the tissue organization, either paraffin embedded or
frozen sections were stained with haematoxylin and eosin.
Immunohistochemistry
The paraffin embedded sections were deparaffinized and rehydrated as
usual and for antigen retrieval boiled 10 min. in sodium citrate buffer
(10 mM, pH 6.0; Bio-Optica) or treated for 20 min. at 90–92°C in Tris
buffer (10 mM) with ethylenediaminetetraacetic acid (1 mM, pH 9.0), as
appropriate, followed by cooling to room temperature (RT).
For fluorescence microscope examination, the frozen and the
deparaffinized sections were washed in PBS and blocked for 20 min. at
RT with 1.5% bovine serum albumin (BSA; Applichem, Darmstad, Ger-
many) in PBS, plus 0.5% Triton (Sigma-Aldrich, St. Louis, MO, USA)
for the frozen ones. The primary antibodies diluted in PBS were applied
ON at 4°C. The day after, the sections were washed in PBS and incu-
bated for 2 hrs at RT in the dark with appropriate fluorochrome-conju-
gated (AlexaFluor 488- or 568-conjugated) secondary antibodies (goat





Fig. 2 Calcitonin gene-related peptide (CGRP)-IR. Varicose axons are
numerous within the muscularis mucosa and, in the submucosa, close
to the wall of blood vessels and at SMP ganglia. In WRS rats (B),
CGRP-IR is increased at all levels respect to controls (A) and OB/WRS
rats (C). Bar: A–C = 25 lm. (D) The quantification of all the nerve
fibres shows a statistical significant increase in the WRS rats
(***P < 0.0001).
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Invitrogen, San Diego, CA, USA) diluted 1:333 in PBS. The sections
were washed in PBS and mounted in an aqueous medium (Immuno-
Mount; Thermo scientific, Rockford, IL, USA) with or without 40,6-dia-
midino-2-phenylindole (Sigma-Aldrich). The immunoreaction products
were observed under an epifluorescence Zeiss Axioskop microscope
(Zeiss, Oberkochen, Germany) using 488-, 568- and 370-nm excita-
tion wavelength for the green, red and blue fluorescent labels, respec-
tively, and the fluorescence images were captured using a Leica
DFC310 FX 1.4-megapixel digital camera, equipped with the Leica soft-
ware application suite LAS V3.8 (Leica Microsystems, Mannheim,
Germany).
For light microscope examination, after deparaffinization, rehydration
and antigen retrieval phase as reported, the sections were treated with 3%
H2O2 in PBS for 5 min. to block endogenous peroxidase activity. After
washing, the sections were incubated with 1.5% BSA in PBS for 20 min.
at RT. The anti-S100b primary antibody was applied ON at 4°C. The day
after, the sections were incubated with the biotinylated secondary anti-
body diluted 1:300 (goat anti-mouse; Jackson ImmunoResearch, West
Grove, PA, USA) in PBS for 2 hrs at RT. Subsequently, the sections were
washed, treated with ABC Reagent (Vectastain ABC/Elite Kit; Vector
Laboratories, Burlingame, CA, USA) for 20 min. and developed with 3,30-
diaminobenzidine (DAB; Sigma-Aldrich), as chromogen. Sections were
Table 1 Results of quantitative analysis; *p<0.02, **p<0.001, ***p<0.0001.
Neuron number CTRL WRS OB/WRS
NK1r
MP 41.37  3.547 25.71  2.031* 35.12  2.031
SMP 6.500  0.500 9.500  1.555 7.000  0.577
nNOS
MP 35.25  2.358 24.06  1.253** 33.94  2.203
SMP 10.00  1.398 3.600  0.921* 6.600  1.024*
VIP
MP 39.37  0.895 30.44  1.554* 38.25  3.660
SMP 21.50  2.001 15.29  0.905* 19.75  1.090
ChAT
MP 97.00  4.137 86.87  2.782 74.33  4.621**
SMP 18.73  1.649 17.80  1.868 14.33  1.476
CRF1r
MP 28.63  4.799 52.64  7.838* 35.07  3.446
CRF2r
MP 55.30  3.019 77.40  4.290*** 78.50  3.349***
Integrated density CTRL WRS OB/WRS
nNOS
Muscle wall 37,366  207 22,339  134*** 36,659  180
SP
Muscle wall 8079  697 5479  462* 7701  719
CGRP
Mucosa-submucosa 693.7  108 1130  111*** 515.4  56.07
S100b
Muscle wall 20,019  188 11,844  167** 20,588  153
Mucosa-submucosa 6496  525 1879  294*** 5961  518
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counter-stained with haematoxylin. After washing in PBS, the sections
were mounted in an aqueous medium (Sigma-Aldrich) and observed
under the Microstar IV light microscope (Reichert Technologies, Reichert
Inc, Depew, USA). For CRF1r staining, the procedure described by [13,
14] has been followed. Endogenous peroxidase activity was blocked by
incubation for 30 min. with 0.3% H2O2 in PBS and nonspecific reaction
was blocked by incubation in 3% normal donkey serum (60 mg/ml; Jack-
son ImmunoResearch) for 30 min. at RT. Sections were incubated with
anti-CRF1r in PBS 0.3% Triton X-100 and the day after with the secondary
antibody (rabbit anti-goat; Jackson ImmunoResearch). Finally, these sec-
tions were processed for avidin-biotin-peroxidase procedure using DAB
and observed under the light microscope.
Negative controls were performed omitting the primary antibody or
using the specific blocking peptide to exclude the presence of nonspecific
staining.
Western blot
The procedure followed foreseen the protein content extraction from
full-thickness samples of ascending colon. After spectrophotometrically
protein quantification, samples and appropriate molecular-weight mark-
ers were resolved by standard electrophoresis and blotted onto
polyvinylidene fluoride microporous membrane. After the incubation
with primary and peroxidase-conjugated secondary antibodies, the
immunoreaction products were revealed by chemiluminescence reagent.
To normalize the values of the antibody, the runs were also immunos-
tained with anti-b-actin, assumed as housekeeping protein. The details
about western blot procedures were explained in Data S1.
Information on primary antibody sources and used concentrations
for fluorescence, light microscope examination and WB analysis is
shown in Table S2.
Quantitative and statistical analysis
The faecal pellets and AC number was quantified and expressed as
number  S.E.M. A quantitative analysis of the immunoreactive (IR)
structures was done by the acquisition of digitized images of the label-
ling (1 section/animal; 5 animals/group) using 209 or 409 objectives,
as appropriate; attention was made to avoid overlapping between the
adjacent portions. Each image was analysed using ImageJ (NIH,
Bethesda, ML, USA) to evaluate the intensity of labelling and to quantify
the area of the IR structures. The photographs’ threshold values were
set to analyse the structures of interest exclusively. The labelling was
converted to a binary image and the number of pixels and the IR inten-
sity were measured. The results are expressed as optical den-
sity  S.E.M. The quantitative analysis of the number of IR neurons or
inflammatory cells was done by two observers, blind to each other,
along the entire section (three sections/animal; five animals/group) and
expressed as number  S.E.M. The quantitative analysis of western
blot-IR bands was performed by computer-assisted densitometry by
using the QuantityOne analysis software (Bio-Rad, Hercules, CA, USA)
with each band corresponding to a single specimen. The results for the
protein of interest were normalized to the corresponding b-actin band.
Statistical analysis was performed by one-way ANOVA followed by
Newman–Keuls post-test to compare the three groups. Differences were




A statistically significant increase (P < 0.05) in the weight and
number of faecal pellets was found in rats subjected to WRS as
compared to controls (2869  416 versus 986  219 mg and
10.63  1.97 versus 5.88  1.27 respectively). Acute administra-
tion of OB (2 and 20 mg/kg p.o.) did not affect these parameters
(data not shown). AC numbers of rats subjected to WRS was
increased only at 1.2 ml distension as compared to controls
(21.00  3.09 versus 14.43  2.62). This increase (35% from
controls) was reduced by 20 mg/kg p.o. OB at 14.63  1.89 and
by 2 mg/kg p.o. OB at 17.88  2.97. On the basis of these
results, the dose of 20 mg/kg OB was chosen for the next
experiments.
Second phase
Number and weight of faecal pellets showed a statistically signifi-
cant increase (P < 0.05) in the WRS group as compared to con-
trol one (10.0  1.64 versus 7.25  1.10 and 2724  364
versus 1146  151 mg respectively). The repeated treatment with
20 mg/kg of OB was unable to affect these parameters (values in
number and weight of faecal pellets were: 10.25  1.22 and
2327  277 mg). Increase in distension volume produced an
increase in AC in all groups. Controls: 3.75  1.39, 7.75  0.86,
13.25  1.79, 21.75  2.30; WRS rats: 4.13  1.11, 5.88 
1.57, 18.13  1.92, 29.00  2.00; OB/WRS rats: 1.75  0.56,
6.50  1.73, 17.38  1.61, 25.25  3.52 at 0.0, 0.4, 0.8 and
1.2 ml of volume distension, respectively. The increase was statis-
tically significant (P < 0.05) as compared to 0 volume distension
at 0.4, 0.8 and 1.2 ml of volume distension in controls and at 0.8
and 1.2 ml in WRS and OB treated animals. Comparison between
controls and WRS rats showed a statistically significant increase
(P < 0.05) in the latter group at 0.8 and 1.2 ml of volume
distension. OB/WRS did not show any significant difference in the
number of AC at any volume of distension examined as compared
to WRS rats. However, at variance with WRS rats, the number of
AC in OB treated rats at 1.2 ml of volume distention was not sig-
nificantly different from controls. To note, in the absence of vol-
ume distension, OB/WRS group showed a statistically significant
decrease (P < 0.05) in number of AC (1.75  0.56) versus WRS
(4.13  1.11) and control rats (3.75  1.39).
Morphological findings
Histological evaluation of the colonic wall with haematoxylin and
eosin showed a substantial integrity of mucosa, submucosa and mus-
cle wall in all groups of animals. Similarly, the labelling with the pan-
neuronal marker PGP9.5 showed no changes among the groups in
the total number of neurons either in the myenteric or submucous
plexus (SMP; data not shown).
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Lamina propria and submucosa
Haematoxylin and eosin staining and c-kit-IR labelling revealed the
presence of a mild inflammation consisting in clusters of immunity
cells beneath the lining epithelium and in the mucosa a significant increase
in eosinophilic granulocytes (controls: 51.50  6.652; WRS:
76.50  3.775; OB/WRS: 71.50  6.764, P < 0.05) andmast cells (con-
trols: 166  7.371; WRS: 231.3  7.219; OB/WRS: 221.3  4.978,
P < 0.001), inWRS and OB/WRS rats compared to controls.
CGRP-IR nerve fibres were significantly increased in WRS rats.
This increase was prevented by OB treatment, especially in the sub-
mucosa (Fig. 2A–D and Table 1).
S100b-IR structures were significantly decreased in WRS rats
compared to controls. This decrease was not present in OB/WRS rats
(Table 1).
VIP-IR neurons were decreased in WRS rats. This decrease was
prevented in OB/WRS group (Fig. 3A–D and Table 1).
nNOS-IR neurons were significantly decreased either in WRS or
OB/WRS rats compared to controls (Table 1).
NK1r- and ChAT-IR neuron number was unchanged in the SMP
among the groups of animals (Table 1). To note, whereas in controls
and OB/WRS rats, the NK1r-IR labelling was located along the plasma
membrane, in WRS rats, it was mainly distributed in the cytoplasm.
Muscle wall
c-kit-IR interstitial cells of Cajal showed no changes in organization,
size, shape and number; however, the labelling distribution appeared
clustered in OB/WRS and WRS rats instead to be uniformly dis-
tributed along the cell profile as in controls (Fig. 4A–C).
Mr2-IR in the smooth muscle cells was decreased in WRS rats
compared to controls and OB/WRS rats (Fig. 5A–C). Quantization of
the receptor by WB confirmed this decrease (Fig. 5D).
ChAT-IR neuron number showed no change in WRS rats while it
was significantly decreased in OB/WRS rats (Fig. 5E–G and Table 1).
S100b-IR structures were significantly reduced in WRS rats com-
pared to controls; this decrease was prevented by OB treatment
(Table 1).
CRF1r- and CRF2r-IR neurons (Fig. 6A–F) were significantly
increased in WRS rats compared to controls. To note, OB prevented
the CRF1r increase exclusively (Fig. 6G and H, Table 1).
VIP-, nNOS- and NK1r-IR neuron number was significantly
decreased in WRS rats; these decreases were completely prevented in
OB treated rats (Figs 3A–C, E and 7D; Table 1). Similar to the SMP neu-
rons, in controls and OB/WRS rats the NK1r-IR labelling was mostly dis-
tributed along the plasma membrane (Fig. 7A and C), while in WRS rats
the majority of the neurons were labelled also in the cytoplasm (Fig. 7B).
SP- and nNOS-IR nerve structures were significantly decreased in
WRS rats; these decreases were undetected in OB/WRS group of ani-
mals (Table 1).
Discussion
This study demonstrates that repeated OB administration in rats sub-
jected to acute WRS is able to counteract most of the morphological
changes caused by this psychosocial stressor in the colonic wall. In
particular, the drug prevents the decrease in SP-, NK1r-, nNOS-, VIP-





Fig. 3 Vasoactive intestinal peptide (VIP)-IR. Numerous IR neurons are
seen at both myenteric (MP) and submucous (SMP) plexuses in all the
animals (A–C); however, in the WRS rats, their number is significantly
decreased (D and E) respect to controls and OB/WRS animals
(*P < 0.02). Bar: A–C = 50 lm.
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detected in WRS rats. As expected, OB does not interfere with the
mild mucosal inflammation because of WRS. Interestingly, OB treat-
ment per se increases the Mr2 expression in the muscle wall and
decreases the number of the ChAT-IR myenteric neurons. Notewor-
thy, OB does not affect the increase in CRF2r-IR neurons observed in




Fig. 4 Interstitial cells of Cajal (ICC) identi-
fiable by their c-kit-IR. In A–C, typical ICC,
with a spindle shape and a peripheral c-
kit-positivity, are located at the submu-
cous border of the circular muscle layer.
In both WRS (B) and OB/WRS (C) rats
the c-kit labelling is discontinuous instead
to be uniformly distributed, as in controls
(A), along the entire cell contour. Bar: A–








Fig. 5 (A–D) Muscarinic receptor type 2
(Mr2)-IR. Smooth muscle cells are inten-
sely stained. However, intensity is lower
in the WRS (B) rats compared to controls
(A) and OB/WRS (C) ones. Bar: A–
C = 50 lm. (D) Western blot shows that
the Mr2-IR decrease observed in the WRS
rats is not significant. (E–G) Choline acetyl
transferase-IR (ChAT)-IR. Numerous IR
neurons are seen in all the animals (E and
F). Bar: E and F = 50 lm. (G) The quan-
tification of the myenteric ones shows that
in the OB/WRS animals, there is a signifi-
cant decrease in their number respect to
controls and WRS rats (**P < 0.001).
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significantly reduce the number of spontaneous AC compared to
WRS and control rats but not of those induced by volume distention.
Several studies have been addressed to identify the OB molecular
targets [15, 16]. The results obtained in in vitro experiments after
acute exposition of rat colonic strips to the drug showed that OB
behaves as antagonist of the L-type Ca2+ channel, M2 and neurokinin
receptors [3, 17, 18]. These effects were considered the consequence
of the OB interaction with the colonic smooth muscle cells because of
the very poor systemic absorption of the drug [2]. Recently, a series
of publications where OB was administered repeatedly has allowed to
extend the knowledge on the complexity of OB pharmacology
unmasking a constant involvement of the enteric nervous system in
mediating the drug actions [6–8].
Otilonium bromide is commonly used to control the main symp-
toms of IBS, a chronic disease characterized by visceral pain and/or
discomfort, hypersensitivity and abnormal motor responses [19].
Although the aetiopathogenesis of IBS is only partially understood, a
main role has been attributed to psychosocial stressors of different
origin [20, 21]. The WRS is considered a psychosocial stress model
adequate to reproduce in the animals, some of the typical symptoms
and signs of IBS [22–24]. Accordingly, we recently reported func-
tional and morphological alterations in WRS rat similar to those
described in IBS patients [12] and, presently, we demonstrate that
repeated OB administration prevents most of the changes caused by
the WRS, particularly those on the enteric nervous system. However,
the cellular mechanism through which OB could interfere with the
nerve structures is undefined. Among the several pharmacological
properties attributed to OB, the inhibition of the calcium entry by
binding to the L-type Ca2+ channels has been considered the most
significant [3, 6, 16, 17]. In this respect, since the neurons express
the L-type Ca2+ channels, the possibility that OB, blocking these chan-
nels, could modify the neuronal response to physiological [6, 7] or
pathological [12] stimuli has to be considered. As a matter of fact the
variations in the neurotransmitters’ expression found in the myenteric
neurons after repeated OB treatment [6–8] are coupled to significant
changes in neuronal activity [8].
Of particular interest are the changes in the CRF1r and CRF2r
expression presently detected in the myenteric neurons of WRS
rats and in WRS rats pre-treated with OB. The presence of these
two receptors was already demonstrated either by PCR techniques
in the human colon [13] or by immunohistochemistry in the rat
colon [14] and it was shown that the CRF2r is higher expressed
compared to the CRF1r. In agreement, we presently detect a
greater number of CRF2r-IR neurons compared to the CRF1r-IR
ones. Pharmacological studies have shown that the endogenous
ligand cortical releasing factor (CRF) shows higher affinity to the
CRF1r respect to the CRF2r [14, 25]. Cortical releasing factor is
considered the primary hypothalamic mediator of the mammalian
neuroendocrine and behavioural responses to stress [26] and the
adverse gastrointestinal effects (visceral hypersensitivity, increased
colonic transit) caused by its injection or by psychosocial stres-








Fig. 6 Corticotrophin releasing factor
receptor 1 and 2 (CRF1r and CRF2r)-IR.
The labelling is expressed by numerous
myenteric neurons in controls (A and D),
WRS (B and E) and OB/WRS (C and F)
rats. Bar: A–F = 50 lm. (G) The quantifi-
cation of the CRF1r-IR neurons shows a
statistically significant increase in stressed
animals that was prevented in OB treated
rats (*P < 0.02). (H) The quantification of
CRF2r-IR neurons shows a statistical sig-
nificant increase in WRS and OB/WRS
rats (***P < 0.0001).
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the CRF2r role, it was reported that injection of selective agonists
did not provoke any measurable response in the rat colonic wall
[14] and it has been suggested that the CRF2r activation could
negatively modulate the CRF1r mediated responses. In fact, the
administration of the selective CRF2r agonist, Urocortin 2, inhibits
the CRF1r mediated stimulation of colonic motor function induced
by acute partial restrain stress or by CRF injection [14]. In a
recent paper, we reported that WRS causes an increase in the
CRF1r expressing neurons in the myenteric plexus of rat colon.
Presently, we show also a significant increase in the CRF2r-IR
myenteric neurons in WRS rats. Thus, it can be inferred that
stress causes a complex neuronal response consisting not only of
a predictable increase in CRF1r, as mediator for the adverse local
effects, but also of an unexpected increase in CRF2r. On the basis
of the literature, this latter finding might be interpreted as an
attempt to cope to the CRF1r mediated stress effects that could
bring to an overdrive state and predispose to diseases. The rele-
vance of the CFR2r in determining the outcome of a stress condi-
tion is likely underestimate. In a recent report on the lack of a
CRF1r antagonist efficacy to ameliorate colonic symptoms in IBS
patients [29], it has been suggested that impairment in the
CRF1r-CRF2r integrated response might be implicated in the
pathogenesis of this disease.
In the muscle wall of WRS rats, the expression of the inhibitory
(nNOS, VIP) and excitatory (SP/NK1r) neurotransmitters investigated
is decreased suggesting that stress causes an impairment of the neu-
ronal activity. Reasonably, this impairment is triggered by the CRF
through its receptors. To note, the CRF, beyond the central nervous
system, is also expressed and likely released by the enteric neurons
and, in stress conditions, the number of the neurons expressing the
CRF is increased [13]. Few and partial information is available on
the specific neuronal population releasing the CRF and/or expressing
the CRF receptors [30, 31]. Noteworthy, presently, we show that
repeated administration of OB prevents almost of the neurotransmit-
ters’ decreases and the overexpression of the CRF1r in the myenteric
plexus without modifying that of the CRF2r. Our experimental condi-
tions do not allow to establish a direct relationship between the two
events; however, the ability of OB to prevent the neurotransmitters’
changes due to stress and the reduction in the excitatory ChAT
expressing neurons, caused by the drug per se, might explain the
spasmolytic activity exerted by OB and the relief from most of the IBS
symptoms.
As expected OB does not show any anti-inflammatory activity
when measured as cell infiltrate and mast cell increase. However,
through its ability to interact with the nerve structures, OB prevents
the increase in the CGRP expression in the submucosa and mucosa
of WRS rats. CGRP is mainly expressed by sensory neurons and in
IBS patients or in rats underwent to maternal deprivation, CGRP-posi-
tive fibres are increased and strictly associated with mast cells [32–
34]. Moreover, stress conditions favour mast cell degranulation and
release of inflammatory mediators able to sensitize sensory afferents
such as those carrying CGRP [35, 36]. Furthermore, the rectal biopsy
samples taken from patients with well-characterized rectal hypersen-
sitivity showed a marked increase in submucosal CGRP [11]. There-
fore, although OB does not interfere with the mast cell increase
present in WRS rats, it is reasonable to infer that, because of its abil-
ity to prevent the overexpression of CGRP, it might also ameliorate
symptoms such as pain.
The results obtained with the functional studies appear contrast-
ing also in view of the known OB efficacy in counteract visceral sensi-
tivity in IBS patients [37, 38]. Interestingly, OB causes a significant





Fig. 7 Neurokinin receptor 1 (NK1r)-IR. In control and OB/WRS rats, the
NK1r labelling is mainly located along the neuronal plasma membrane
(A and C) while in the WRS rats (B) the majority of the neurons are
labelled also in the cytoplasm. MP: myenteric plexus. Bar: A–
C = 25 lm. (D) The quantification of the myenteric neurons shows that
in the WRS animals, there is a significant decrease in their number
respect to controls and OB/WRS rats (*P < 0.02).
ª 2016 The Authors.
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WRS rats. This datum indicates that OB induces muscle relaxation,
thus reducing the visceral motility. The inability of OB to reduce the
number of AC because of volume distention might be explained by
the modalities provided by the CRD test. In fact, it has been reported
that the application of a progressive volume of distention increasing
the painful sensations recruits central efferent fibres [22] insensitive
to OB effects [3]. Accordingly, when this test was applied to measure
the efficacy of other drugs known to be able to reduce the visceral
sensitivity in humans, the results failed [39].
In conclusion, this study confirms the WRS as a model suitable to
mimic most of the IBS symptomatology and adequate to investigate
the OB cellular targets to ameliorate our understanding of the drug
mechanisms of action in IBS. The findings obtained indicate that most
of the OB activity is exerted at the enteric nervous system level by
preventing the neuronal changes caused by the stress. How OB act at
the cellular level is not defined yet; however, its ability to block the
calcium entry could represent a plausible explanation. This pharmaco-
logical property might play a role also in avoiding the increase in the
neuronal cells that express the CRF1r, as observed in the WRS rats.
We are aware that the combination of a repeatedly pre-treatment with
the application of an acute model of stress might represent a limita-
tion of this study. However, the results obtained in the clinical studies
of OB efficacy in IBS patients [40] have brought to hypothesize that
cyclic or intermittent treatment, independently on the presence of the
IBS symptoms, might be an adequate therapeutic strategy to manage
the IBS [41].
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